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People Living with HIV (PLHIV) should be screened for tuberculosis (TB) at every visit to
the HIV care and treatment clinic (CTC), and those with positive results on screening
should undergo further diagnostic investigations. We evaluated the performance of
the TB diagnosis cascade among PLHIV attending CTC between January 2012 and
December 2016 in three regions of Tanzania: Dar es Salaam, Iringa, and Njombe.
We used descriptive epidemiology to evaluate performance and logistic regression to
determine odds ratios (OR) for factors associated with TB screening and further TB
diagnosis after positive TB screening. We analyzed 169,741 PLHIV whomade 2,638,876
visits to CTC between January 2012 and December 2016. We excluded 2,074 (0.80%)
visits as these involved PLHIV enrolled in CTC with a prior TB disease diagnosis. Of the
2,636,802 visits, 2,524,494 (95.67%) had TB screening according to national guidelines,
of which 88,028 (3.49%) had TB screening positive results. Of the 88,028 visits with
a positive TB screening, 27,810 (31.59%) had no records for further TB diagnosis
following positive TB screening. Of all visits with positive TB screening, 32,986 (37.50%)
had a TB disease diagnosis. On multivariate logistic regression, those who visited with
World Health Organization (WHO) clinical stage four (aOR = 3.61, 95% CI 3.48–3.75,
P< 0.001), enrolled in health center (aOR= 1.26, 95%CI 1.24–1.29, P< 0.001), enrolled
in Iringa region (aOR = 1.54, 95% CI 1.50–1.57, P < 0.001), and enrolled in 2015 (aOR
= 1.20, 95% CI 1.18–1.24, P < 0.001) were more likely to have no TB screening. Visits
involving those who were of the female sex (aOR= 1.14, 95% CI 1.11–1.18, P < 0.001),
enrolled in Njombe region (aOR = 4.36, 95% CI 4.09–4.65, P < 0.001), and enrolled in
2016 (aOR= 2.62, 95% CI 2.49–2.77, P < 0.001) were more likely to have no further TB
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diagnosis after positive TB screening. The study documented high performance of TB
screening for PLHIV in HIV CTCs but a low transition of presumptive TB case undergoing
further investigations. Better systems are needed for ensuring presumptive TB cases are
diagnosed including using more efficient diagnostic methods like Gene pert.
Keywords: tuberculosis, screening, diagnosis, HIV, Tanzania
INTRODUCTION
Despite wide use of antiretroviral (ARV) drugs, tuberculosis (TB)
is still a public health challenge for People Living with HIV
(PLHIV) (1). In autopsy studies among PLHIV in Africa, TB was
present in 21–54% of people, and TB was the cause of death in
32–45% of the PLHIV in the study (2). The risk of TB is higher
among PLHIV; HIV-positive individuals are up to 26 times
more likely to have active TB disease compared to HIV negative
individuals, and globally at least 30% of PLHIV have latent TB
(3). Worldwide, in 2018, 10.0 million TB cases were notified, and
of these 24% were from the African continent. TBHIV accounted
for 8.6% of the notified TB cases. Of the 1.5 million TB deaths
reported in 2018, 17% (251,000) of deaths were HIV positive (1).
In Tanzania, which is among 30 high TB-burdened countries, a
total of 142,000 TB cases were diagnosed with TB disease in 2018,
of which 40,000 (28%) were HIV positive (1).
To reduce TB among PLHIV, the World Health Organization
(WHO) recommends Intensified TB case finding (ICF) among
PLHIV attending HIV care and treatment clinics (CTC), which
entails active TB screening for symptoms and signs using
standardized TB screening questions (4). In Tanzania, those who
screen positive undergo further TB diagnosis according to the
National Guidelines (5). TB screening using symptoms and signs
among PLHIV is important to increase TB disease diagnosis, and
ICF is thus a gateway to TB management among PLHIV (6, 7).
There is an urgency to build better TB prevention in resource-
limited settings, but to do so we need to evaluate how well the
current cascade is working (8).
TB diagnosis cascade among PLHIV in CTCs faces a number
of challenges, including those lost to follow up in the diagnosis
cascade (9, 10). A study in Northern Uganda looking at improved
TB case notification among both HIV-positive and HIV-negative
individuals found a TB positivity rate of 3.5% among the 385
HIV positive who were positive on the screening questions. A
prospective study in India found that 30% screened TB positive,
and 35% of these were referred for TB diagnostic tests, and
15% had confirmed TB (11). In Kenya, a study reported a high
TB screening among 1,020 newly diagnosed PLHIV; 98% of
PLHIV were screened, but only 16% of those screened positive
underwent further TB diagnosis evaluation, and 26 (2.6%) were
eventually diagnosed with TB (12). In Ethiopia, 72% of PLHIV
with positive TB screening were linked to sputummicroscopy for
TB with the remaining PLHIV diagnosed using other methods
(13). A study conducted in Ghana also found that sputum
for smear microscopy was requested for 58.7% of those who
needed (14).
In this paper, we analyzed routine HIV data from PLHIV
enrolled in CTC from January 2012 and December 2016.
We evaluated the performance of the TB diagnosis cascade
for PLHIV attending CTC and determined factors associated
with TB screening and further TB diagnosis after positive TB
screening. The aim of the paper was to provide evidence to
the Tanzanian Ministry of Health Community Development,
Gender, Elderly and Children (MoHCDGE) on the performance
of TB diagnosis cascade among PLHIV attending CTC in
Tanzania for quality improvement. The findings from this study
will also be applicable to other developing countries where HIV
and TB are also prevalent.
MATERIALS AND METHODS
The study involved electronic patients’ records that were
routinely collected and contained in the CTC database from 317
health facilities in three regions: Iringa, Njombe, and Dar-es-
Salaam. The study used retrospective data from PLHIV enrolled
in CTC from January 2012 to December 2016. PLHIV enrolled
into CTCwith an existing diagnosis of TB disease from TB clinics
were excluded from the study.
The United Republic of Tanzania comprises of mainland
Tanzania and Zanzibar with a population of about 44 million in
2012 (15). Tanzania Mainland has a generalized HIV epidemic
with the first case of HIV reported in 1983. By 1986, all regions
in the country had reported at least one case (16). The Tanzania
HIV Indicator Survey showed an overall prevalence of HIV of
5.1% in 2011/2012 and 4.7% in 2016/17. The three regions were
purposely selected as they had higher HIV prevalence according
to the recent National HIV survey (17).
Tanzania have rolled out widespread, freely available
antiretroviral therapy services in HIV CTC ever since 2004. For
TB management in CTC, PLHIV were screened for TB using
the standardized WHO questions at every visit to the clinics.
Those who screened positive were further evaluated for TB
disease using either sputum examination, radiology, or clinical
diagnosis according to a TB management algorithm (5). Those
with confirmed TB disease were started on anti-TB therapy.
PLHIV who were negative on the TB screening were assessed for
their eligibility for Isoniazid Preventive Therapy (IPT). Those
who became eligible for IPT were kept on daily Isoniazid tablets
for 6 months to prevent active TB disease. TB infection control
measures were another set of interventions implemented in
HIV clinics to prevent TB transmission among PLHIV and
staff (Figure 1).
Data Extraction Process and Variables
Descriptions
De-identified secondary data were extracted from the main
national HIV care and treatment database. The independent
variables of interest included age, sex, WHO clinical stage, health
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FIGURE 1 | TB diagnosis cascade in HIV care and treatment clinics.
facility type (Hospital, Health center or Dispensary), health
facility ownership (public or private/Faith Based Organization),
region during CTC enrolment, TB screening status (screen or not
screened), and TB diagnosis status after positive TB screening
(Further TB diagnosis or no further TB diagnosis). The final
dataset excluded all PLHIV with known TB diagnosis before
CTC enrolment.
Data Analysis
Stata version 14 (Stata Corporation, College Station, Texas, USA)
was used for data cleaning, merging, and analysis. Descriptive
statistics used mean and standard deviation for continuous
variables and frequencies and proportions for categorical
variables. For each estimate, a 95% Confidence Interval (95%
CI) was also calculated. Bivariate logistic regression was used
to determine odds ratios (OR), and 95% CI for the association
between independent and dependent variables. The likelihood
ratio test was used to obtain chi-square statistic and p-value
for each analysis. Finally, all independent variables with a p of
≤0.2 in a bivariate analysis were subjected in a multivariate
logistic regression to determine the adjusted OR and 95% CI for
independent factors associated with TB screening and further
TB diagnosis after positive TB screening. In the final analysis, a
cut-off p ≤ 0.05 was considered statistically significant.
Ethical Consideration
The study involved secondary analysis of unlinked data; hence,
there was no contact with human subjects. The permission to
conduct the study was obtained from the National Institute
of Medical Research-Tanzania, and permission to use routinely
collected data was obtained from National AIDS Control
Program by signing a data transfer agreement. This study was
carried out as part of the PhD research by Werner Maokola with
ethical permission for the PhD from KCMU college.
RESULTS
A total of 171,743 PLHIV were enrolled in HIV CTC in the
Dar es Salaam, Iringa, and Njombe regions from January 2012
to December 2016. The mean age for the PLHIV was 35 years
(Range: 0–97 years). A total of 2,074 PLHIV were not included
in the analysis as they had TB disease before CTC enrolment. Of
the remaining 171,669, the majority of PLHIV were aged 25–49
years; 123,581 (71.99%), females; 117,925 (68.69%), had working
functional status; 164,076 (95.58%), and had WHO clinical stage
one; 62,535 (36.43%). Most of the study participants were also
enrolled in 2016, 37,788 (22.01%), were from dispensary level,
65,405 (38.10%), and were from public health facilities, 123,964
(72.2%) (Table 1).
The study cohort made a total of 2,638,876 visits during
the follow-up period; however, 2,074 visits (0.80%) visits were
excluded from the analysis as they involved TB disease diagnosis
before CTC enrolment. Of the remaining 2,636,802 visits,
2,524,494 (95.67%) had TB screening. Of these, 88,028 (3.49%)
had TB-positive screening results. Of the visits with TB screening,
48,930 (55.58%) had sputum examinations, 10,496 (11.92%) had
a chest X-ray, 792 (0.90%) had a TB diagnosis through clinical
criteria, and 27,810 had no records for further TB diagnosis
following positive TB screening. Of all visitors with a positive TB
screening, 32,986 (37.50%) had a TB disease diagnosis (Figure 2).
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TABLE 1 | Baseline characteristics of PLHIV enrolled in CTC between 2012 and 2016 in three regions of Tanzania N = 171,669.
Variable Total, N Dar-es-Salaam, N Iringa, N Njombe, N
Individual level factors
Age (years) Mean = 35 years, SD = 12 years, Range = 0–97 years
<1 1,361 (0.79%) 946 (0.77%) 183 (0.92%) 232 (0.81%)
1–4 3,497 (2.04%) 2,144 (1.74%) 569 (2.88%) 784 (2.75%)
5–9 2,84 (1.65%) 1,707 (1.38%) 497 (2.51%) 637 (2.23%)
10–19 7,564 (4.41%) 5,103 (4.14%) 884 (4.47%) 1,577 (5.52%)
20–24 16,453 (9.58%) 11,781 (9.55%) 1,66 (8.42%) 3,006 (10.53%)
25–49 123,581 (71.99%) 89,722 (72.75%) 13,998 (70.73%) 19,861 (69.57%)
>50 16,363 (9.53%) 11,92 (9.67%) 1,990 (10.06%) 2,452 (8.59%)
Missing 9 (0.01%) 5 (0.00%) 3 (0.02%) 1 (0.00%)
Sex Male 53,744 (31.31%) 34,657 (28.10%) 8,034 (40.59%) 11,054 (38.72%)
Female 117,9275 (68.69%) 88,672 (71.90%) 11,757 (59.41%) 17,496 (61.28%)
Functional status Ambulatory 5,426 (3.16%) 3,634 (2.95%) 1,078 (5.45%) 713 (2.50%)
Bedridden 1,419 (0.83%) 1,061 (0.86%) 181 (0.91%) 177 (0.62%)
Working 164,076 (95.58%) 118,038 (95.71%) 18,478 (93.37%) 27,560 (96.53%)
Missing 749 (0.44%) 596 (0.48%) 53 (0.27%) 100 (0.35%)
WHO stage Stage 1 62,535 (36.43%) 48,400 (39.24%) 5,140 (25.97%) 8,995 (31.51%)
Stage 2 40,347 (23.50%) 26,587 (21.56%) 5,707 (28.84%) 8,053 (28.21%)
Stage 3 53,846 (31.37%) 38,648 (31.34%) 7,062 (35.68%) 8,136 (28.50%)
Stage 4 12,748 (7.43%) 8,078 (6.55%) 1,580 (7.98%) 3,090 (10.82%)
Missing 2,193 (1.28%) 1,616 (1.31%) 301 (1.52%) 276 (0.97%)
Enrolment year 2012 31,038 (18.08%) 20,359 (16.51%) 5,083 (25.68%) 5,596 (19.60%)
2013 33,403 (19.46%) 24,230 (19.65%) 3,746 (18.93%) 5,427 (19.01%)
2014 36,091 (21.02%) 26,232 (21.27%) 3,718 (18.79%) 6,141 (21.51%)
2015 33,349 (19.43%) 24,433 (19.81%) 3,566 (17.97%) 5,360 (18.77%)
2016 37,788 (22.01%) 28,075 (22.76%) 3,687 (18.63%) 6,026 (21.11%)
Type of health facility Dispensary 65,405 (38.10%) 52,236 (42.35%) 7,409 (37.44%) 5,760 (20.18%)
Health center 45,659 (26.60%) 27,910 (22.63%) 8,633 (43.62%) 9,117 (31.93%)
Hospital 60,606 (35.30%) 43,183 (35.01%) 3,749 (18.94%) 13,673 (47.89%)
Health Facility ownership Private 47,705 (27.79%) 30,962 (25.11%) 10,149 (51.28%) 6,594 (23.10%)
Public 123,964 (72.21%) 92,367 (74.89%) 9,641 (48.72%) 21,956 (79.90%)
WHO, World Health Organization.
Factors Associated With TB Screening
On multivariate logistic regression analysis, visitors with WHO
clinical stage four (aOR = 3.61, 95% CI 3.48–3.75, P < 0.001)
and who were enrolled in a health center (aOR = 1.26, 95% CI
1.24–1.29, P < 0.001), enrolled in the Iringa region (aOR= 1.54,
95% CI 1.50–1.57, P < 0.001), and enrolled in 2015 (aOR= 1.20,
95% CI 1.18–1.24, P < 0.001) were more likely to have no TB
screening. Visits that involved females (aOR= 0.68, 95%CI 0.67–
0.69, P < 0.001) and working functional status (aOR= 0.45, 95%
CI 0.43–0.48, P < 0.001) were less likely to have no TB screening
(Table 2).
Factors Associated With Further TB
Diagnosis After Positive TB Screening
Upon multivariate logistic regression analyses, visits involving
the female sex (aOR = 1.14, 95% CI 1.11–1.18, P < 0.001),
enrolment in the Njombe region (aOR = 4.36, 95% CI 4.09–
4.65, P < 0.001), and enrolment in 2016 (aOR = 2.62,
95% CI 2.49–2.77, P < 0.001) were more likely to have no
further TB diagnosis after a positive TB screening. Visitors
with working functional status (aOR = 0.62, 95% CI 0.58–
0.67, P < 0.001), enrolment in hospitals (aOR = 0.39,
95% CI 0.38–0.41, P < 0.001), and attending public health
facilities (aOR = 0.68, 95% CI 0.65–0.71) were less likely
to have no further TB diagnosis after positive TB screening
(Table 3).
DISCUSSION
The present study provided an analysis of the TB diagnosis
cascade for PLHIV enrolled in HIV CTCs in three regions
with high HIV prevalence in Tanzania. The study cohort
consisted mainly of all PLHIV attending CTC with majority
at early stages of the infection (WHO clinical stage one
and working functional status). Efforts have been made to
make sure that people know their HIV status and that
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FIGURE 2 | TB diagnosis cascade for PLHIV in HIV CTCs.
those found to be infected enroll into care. TB is the most
common comorbidity among PLHIV, and it is important to
ensure all those enrolled in CTC are assessed, diagnosed,
and treated at every opportunity in accordance with Tanzania
national Guidelines.
Ninety-five percent (95.67%) of the visitors recorded in the
study cohort had TB screening. Routine TB screening is in
line with the WHO recommendations (18), and such high TB
screening scores among PLHIV has also been reported in other
studies (12, 19–21). TB screening is known to be good to rule out
TB disease in PLHIV with a negative predictive value of 97.7%
(22). It is important to know that TB screening is consistently
carried out in all CTC, but we found that TB screening was
unlikely among PLHIV with advanced disease (WHO clinical
Frontiers in Public Health | www.frontiersin.org 5 February 2020 | Volume 7 | Article 404
Maokola et al. TB Diagnostic Cascade Among PLHIV
TABLE 2 | Factors associated with TB screening: N = 2,636,691.
Variable Number not screened (%) Crude Adjusted
OR (95% CI) P-value aOR(95% CI) P-value
Age group (years)
<1 241 (0.21%) 1
1–4 3,416 (2.99%) 1.53 (1.34–1.75) < 0.001 0.99 (0.82–1.19) 0.815
5–9 4,506 (3.95%) 1.87 (1.64–2.13) < 0.001 0.95 (0.79–1.14) 0.600
10–19 5,624 (4.92%) 1.33 (1.17–1.52) < 0.001 0.95 (0.79–1.14) 0.581
20–24 4,704 (4.12%) 0.73 (0.64–0.83) < 0.001 0.95 (0.79–1.14) 0.565
25–49 80,692 (70.66%) 1.04 (0.91–1.18) 0.543 1.04 (0.88–1.25) 0.597
+50 15,022 (13.15%) 1.24 (1.09–1.41) 0.001 0.99 (0.83–1.19) 0.955
Sex
Male 47,466 (41.56%) 1 1
Female 66,742 (58.44%) 0.60 (0.59–0.61) < 0.001 0.68 (0.67–0.69) < 0.001
Functional status
Ambulatory 1,630 (2.94%) 1 1
Bed-ridden 372 (0.67%) 0.57 (0.50–0.62) < 0.001 0.75 (0.66–0.85) < 0.001
Working 53.381 (96.39%) 0.25 (024–0.27) < 0.001 0.45 (0.43–0.48) < 0.001
Who clinical stage
Stage one 9,240 (14.01%) 1 1
Stage two 11,128 (16.87%) 1.48 (1.44–1.52) < 0.001 2.01 (1.94–2.08) < 0.001
Stage three 37,751 (57.23%) 2.50 (2.45–2.56) < 0.001 3.33 (3.23–3.42) < 0.001
Stage four 7,843 (11.89%) 2.49 (2.42–2.57) < 0.001 3.61 (3.48–3.75) < 0.001
Health facility type
Dispensary 42,902 (37.56%) 1 1
Health center 35,043 (30.68%) 1.08 (1.06–1.09) < 0.001 1.26 (1.24–1.29) < 0.001
Hospital 36,263 (31.75%) 0.94 (0.93–0.96) < 0.001 0.94 (0.92–0.96) < 0.001
Health facility ownership
Private 24,698 (21.63%) 1 1
Public 89,510 (78.37%) 1.59 (1.56–1.61) < 0.001 2.39 (2.34–2.45) < 0.001
Region
Dar es Salaam 73,363 (64.24%) 1 1
Iringa 16,386 (14.35%) 1.17 (1.15–1.19) < 0.001 1.54 (1.50–1.57) < 0.001
Njombe 24,459 (21.42%) 1.15 (1.13–1.16) < 0.001 0.21 (0.21–0.22) < 0.001
Enrolment year
2012 23,886 (20.19%) 1 1
2013 24,589 (21.53%) 1.07 (1.05–1.09) < 0.001 1.01 (0.99–1.04) 0.275
2014 24,673 (21.60%) 1.19 (1.17–1.21) 0.001 1.07 (1.04–1.09) < 0.001
2015 21,177 (18.54%) 1.44 (1.42–1.47) < 0.001 1.20 (1.18–1.24) < 0.001
2016 19,883 (17.41%) 1.84 (1.80–1.87) 0.001 1.15 (1.12–1.19) 0.001
stage 4), enrolment in health centers, enrolment in the Iringa
region, and who enrolled in 2015. Health care providers may find
it easier to administer TB screening questionnaire to healthier
PLHIV than to those with unfavorable functional status who
may already have had other investigations for comorbidities.
Our observation that TB screening performance varied across
health facility types, across administrative regions, and across
implementation time calls for tailored interventions to improve
TB screening.
Our study found that only 3.49% of visits resulted in a positive
screening score over a 4 year period. This was similar to a
study in Kenya where routine screening in a cohort of PLHIV
attending HIV services had <1% visits where a positive screen
was recorded (21). In another study in Kenya among 1,060 newly
enrolled PLHIV, 62% reported symptoms of TB, but only 26 cases
of TB were found. This demonstrates the higher prevalence of
symptoms among PLHIV prior to attending HIV services and
the low sensitivity of TB screening (12). Our finding is similar
to other longitudinal repeated screening of cohorts of PLHIV
(21). The lower positive TB screening in cohorts attending HIV
services can be attributed to several factors. In these programs,
ART is now available to all PLHIV, and this is known to reduce
TB morbidity, mortality and incidence (8). Moreover, in 2014,
isoniazid prevention therapy (IPT) was introduced in Tanzania
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TABLE 3 | Factors associated with no further TB diagnosis among screened positive: N = 88,008.






OR(95% CI) P-value aOR(95% CI) P-value
Age group (years)
<1 352 137 (0.49%) 1 1
1–4 2,395 799 (2.87%) 0.79 (0.62–0.99) 0.040 0.90 (0.69–1.17) 0.431
5–9 2,307 954 (3.43%) 1.11 (0.88–1.39) 0.388 1.11 (0.86–1.44) 0.434
10–19 3,811 1,456 (5.24%) 0.97 (0.78–1.21) 0.792 0.98 (0.76–1.26) 0.872
20–24 3,293 1,299 (4.67%) 1.02 (0.82–1.28) 0.848 0.89 (0.69–1.15) 0.376
25–49 63,911 19,533 (70.24%) 0.69 (0.56–0.86) 0.001 0.68 (0.54–0.87) 0.002
50+ 11,939 3,631 (13.06%) 0.69 (0.55–0.85) 0.001 0.71 (0.56–0.91) 0.007
Sex
Male 37,345 11,230 (40.38%) 1
Female 50,683 16,580 (59.62%) 1.13(1.10–1.16) < 0.001 1.14 (1.11–1.18) < 0.001
Functional status
Ambulatory 1,701 (6.12%) 1 1
Bed-ridden 273 (0.98%) 0.92 (0.79–1.07) 0.305 0.81 (0.69–0.96) 0.013
Working 25,799 (92.89%) 0.94 (0.88–0.99) 0.028 0.62 (0.58–0.67) < 0.001
Who clinical stage
Stage one 5,203 2,682 (9.71%) 1 1
Stage two 10,895 5,714 (20.68%) 1.04 (0.97–1.11) 0.286 1.04 (0.97–1.11) 0.307
Stage three 56,865 15,427 (55.84%) 0.35 (0.33–0.37) < 0.001 0.36 (0.34–0.39) < 0.001
Stage four 12,021 3,806 (13.78%) 0.43 (0.41–0.47) < 0.001 0.46 (0.43–0.49) < 0.001
Health facility type
Dispensary 23,195 10,108 (36.35%) 1 1
Health center 19,257 7,192 (25.86%) 0.77 (0.74–0.80) < 0.001 0.78 (0.75–0.82) < 0.001
Hospital 45,576 10,510 (37.79%) 0.39 (0.38–0.40) < 0.001 0.39 (0.38–0.41) < 0.001
Health facility ownership
Private 16,527 6,561 (23.59%) 1 1
Public 71,501 21,249 (76.41%) 0.64 (0.62–0.67) < 0.001 0.68 (0.65–0.71) < 0.001
Region
Dar es Salaam 73,896 22,133 (79.59%) 1 1
Iringa 8,823 2,179 (7.84%) 0.77 (0.73–0.80) < 0.001 0.42 (0.39–0.45) < 0.001
Njombe 5,309 3,498 (12.58%) 4.52 (4.26–4.79) < 0.001 4.36 (4.09–4.65) < 0.001
Enrolment year
2012 24,503 5,898 (21.21%) 1 1
2013 24,474 6,246 (22.46%) 1.08 (1.04–1.13) < 0.001 1.09(1.04–1.14) < 0.001
2014 16,923 5,973 (21.48%) 1.72 (1.65–1.80) < 0.001 1.71 (1.63–1.79) < 0.001
2015 12,251 5,040 (18.12%) 2.20 (2.10–2.31) < 0.001 2.17 (2.06–2.28) < 0.001
2016 9,877 4,653 (16.73%) 2.81 (2.67–2.95) < 0.001 2.62 (2.49–2.77) < 0.001
for PLHIV attending CTC, with a decline in TB incidence over
the 6 years of follow up (23). Conversely, some PLHIV may
not have typical symptoms of TB disease and may be missed
by the screening, although screening is reported to have a 97%
NPV for ruling out TB infection in PLHIV (24). Further analysis
of whether low positive TB screening was a reality or due
to a weaknesses in the screening process will be evaluated in
subsequent analyses.
Up to 31.59% of visits did not receive a further TB diagnosis
procedure after positive TB screening. In our study, we found
that lack of further follow up after a positive TB screening
was higher among females, those enrolled in Njombe region,
and those enrolled in 2016. Studies in Tajikistan and Uganda
reported a loss to follow up in TB diagnosis of 15 and 33.4%,
respectively. A case-control study in Tajikistan documented risk
factors for loss of follow up in TB diagnosis: movements, drug
side effects, previous TB treatment, patient refusal, stigma, and
family problems (25). A retrospective cohort study of 646 records
of PLHIV initiated on ART in Uganda found that loss to follow
up was associated with good health (normal weight), attendance
in Hospitals, and having no telephone contact (26). Resources to
train health care workers have been set aside to make sure that
PLHIV are screened at every clinic visit in Tanzania, but further
resources are needed to ensure the next step in the TB cascade
Frontiers in Public Health | www.frontiersin.org 7 February 2020 | Volume 7 | Article 404
Maokola et al. TB Diagnostic Cascade Among PLHIV
is taken, and further investigations are undertaken on all who
screen positive.
The study found low use of sputum examination for TB
diagnosis (55.58%). This finding is lower than those reported
in Ethiopia and another study in Tanzania. In Ethiopia, the
AFB diagnostic method was up to 72% of all the TB diagnostic
methods (13), whereas in Tanzania, AFB microscopy was
reported to be the most available TB diagnostic method (27).
Generally, our study found lower use of sputum microscopy
examination for TB disease diagnosis unlike in Ethiopia and
Tanzania (13, 27). In Tanzania, a sputum examination is the first
test for TB disease diagnosis. All people presumed to have TB
disease have to undergo a sputum examination. Other diagnostic
tests such as chest radiography and clinical diagnosis come later
in the algorithm (5).
Our study found only 37.50% of visitors among positive TB
screening had TB disease. Such a high TB diseases diagnosis
among PLHIV with positive TB screening results was recorded
elsewhere in Kenya (21). It is important to note that TB screening
tools with high specificity for TB symptoms are important in TB
control as resources for TB diagnosis and will be used efficiently
for those who most likely have TB disease.
CONCLUSION
The study documented the high performance of TB screening for
PLHIV in HIV CTCs, but a low transition of suspected TB cases
undergoing further investigations. Better systems are needed to
ensure suspected TB cases are diagnosed, and this includes using
more efficient diagnostic methods like GeneXpert.
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